[go: up one dir, main page]

AR007097A1 - BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT. - Google Patents

BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT.

Info

Publication number
AR007097A1
AR007097A1 ARP970101977A ARP970101977A AR007097A1 AR 007097 A1 AR007097 A1 AR 007097A1 AR P970101977 A ARP970101977 A AR P970101977A AR P970101977 A ARP970101977 A AR P970101977A AR 007097 A1 AR007097 A1 AR 007097A1
Authority
AR
Argentina
Prior art keywords
compounds
matrix
matrix metaloprotease
biarylacetilene
biarylacethylene
Prior art date
Application number
ARP970101977A
Other languages
Spanish (es)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of AR007097A1 publication Critical patent/AR007097A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se presentan compuestos inhibitorios de la metaloproteasa de matriz, composiciones farmacéuticas de los mismos y el uso de dichos compuestos parapreparar un medicamento útil. Los compuestos tienen la fórmula (I), donde R15 es seleccionadoen tre el grupo que consiste en HOCH2, MeOCH2, (n-Pr)2NCH2,CH3CO2CH2, EtOCO2CH2, HO(CH2)2, CH3CO2(CH2)2, HO2C(CH2)2, OHC(CH2)3, HO(CH2)4, 3-HO-Ph, y PhCH2OCH2; y R16 es seleccionado entre las fórmulas (II). Estoscompuestos son útiles para inhibirlas m etaloproteasas de matriz y, por lo tanto, para combatir los trastornos a los cuales contribuyen las MMP, talescomo la osteoartritis, la artritis reumatoidea, la artritis séptica, las enfermedades periodontales, las úlceras decórnea, la p roteinuria, laenfermedad de aneurisma aórtico, la epidermólisis vesicular distrófica, los tratarnos que producen respuestas inflamatorias, las osteopenias en las quemedia la actividad de MMP, la enfermedad de la articulacióntemporomandibular, l as enfermedades desmielinizantes del sistema nervioso; las metástasis detumores o la pérdida degenerativa de cartílago posterior a la lesión articular traumática, y la trombosis coronaria a partir de la ruptura deplacaateroesclerótica.Matrix metalloprotease inhibitory compounds, pharmaceutical compositions thereof, and the use of such compounds to prepare a useful medicament are presented. The compounds have the formula (I), where R15 is selected from the group consisting of HOCH2, MeOCH2, (n-Pr) 2NCH2, CH3CO2CH2, EtOCO2CH2, HO (CH2) 2, CH3CO2 (CH2) 2, HO2C (CH2) 2, OHC (CH2) 3, HO (CH2) 4, 3-HO-Ph, and PhCH2OCH2; and R16 is selected from formulas (II). These compounds are useful to inhibit matrix methaloproteases and therefore to combat the disorders to which MMPs contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal diseases, corneal ulcers, proteinuria, aortic aneurysm disease, dystrophic vesicular epidermolysis, treatments that produce inflammatory responses, osteopenias in which MMP activity mediates, temporomandibular joint disease, demyelinating diseases of the nervous system; tumor metastases or degenerative cartilage loss after traumatic joint injury; and coronary thrombosis from atherosclerotic plate rupture.

ARP970101977A 1996-05-15 1997-05-12 BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT. AR007097A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64502896A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
AR007097A1 true AR007097A1 (en) 1999-10-13

Family

ID=24587368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101977A AR007097A1 (en) 1996-05-15 1997-05-12 BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT.

Country Status (18)

Country Link
EP (1) EP0912496A1 (en)
JP (1) JP3090957B2 (en)
CN (1) CN1139570C (en)
AR (1) AR007097A1 (en)
AU (1) AU710759B2 (en)
BR (1) BR9709077A (en)
CA (1) CA2253796C (en)
CO (1) CO5080759A1 (en)
HN (1) HN1997000088A (en)
HR (1) HRP970245B1 (en)
ID (1) ID16910A (en)
PA (1) PA8429301A1 (en)
SV (1) SV1997000035A (en)
TN (1) TNSN97084A1 (en)
TW (1) TW381079B (en)
WO (1) WO1997043245A1 (en)
YU (1) YU18697A (en)
ZA (1) ZA974031B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
AR035478A1 (en) * 1999-01-27 2004-06-02 Wyeth Corp AMIDA-HYDROXAMIC ACID, ACETYLLENE, BETA-SULPHONAMIDE AND PHOSPHINIC ACID AS INHIBITORS OF TACE, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
HUE030114T2 (en) * 2010-07-08 2017-04-28 Kaken Pharma Co Ltd N-hydroxyformamide derivative and pharmaceutical containing same
JP2017509665A (en) 2014-04-03 2017-04-06 バイエル ファーマ アクチエンゲゼルシャフト 2,5-Disubstituted cyclopentanecarboxylic acids for the treatment of airway diseases
US20170022171A1 (en) 2014-04-03 2017-01-26 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentanecarboxylic acids and their use
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
DE2112716A1 (en) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Biphenylyl-butyric acid derivs. - anti phlogistics
FR2378741A1 (en) 1977-02-01 1978-08-25 Fabre Sa Pierre GARYL GOXO ISOVALERIC ACIDS WITH ANTIPHLOGISTIC AND ANTALGIC PROPERTIES
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
ZA974033B (en) 1996-05-15 1998-02-19 Bayer Ag Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors.

Also Published As

Publication number Publication date
ID16910A (en) 1997-11-20
JP3090957B2 (en) 2000-09-25
JPH11511179A (en) 1999-09-28
ZA974031B (en) 1998-02-19
BR9709077A (en) 1999-08-03
CN1139570C (en) 2004-02-25
CO5080759A1 (en) 2001-09-25
HRP970245A2 (en) 1998-04-30
AU710759B2 (en) 1999-09-30
TNSN97084A1 (en) 2005-03-15
TW381079B (en) 2000-02-01
CA2253796A1 (en) 1997-11-20
WO1997043245A1 (en) 1997-11-20
CA2253796C (en) 2003-10-28
YU18697A (en) 1999-11-22
SV1997000035A (en) 1999-01-14
PA8429301A1 (en) 2000-05-24
HN1997000088A (en) 1997-06-18
CN1225623A (en) 1999-08-11
AU2938697A (en) 1997-12-05
HRP970245B1 (en) 2002-06-30
EP0912496A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
ES2166823T3 (en) NEW PIRROLIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ATE208397T1 (en) ARYL SUBSTITUTED 5.5 LINKED AROMATIC NITRO COMPOUNDS AS ANTI-INFLAMMATORY ACTIVES
AR029383A1 (en) SMALL MOLECULES, THE INTERMEDIARIES FOR THEIR SYNTHESIS, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT INTENDED FOR TREATMENT OR PROPHYLAXIS OF INFLAMMATORY DISEASES OR MEDIATIONED BY IMMUNE CELLS
ATE288897T1 (en) POLYMORPHIC CRYSTALLINE FORMS OF CELEKOXIB
BR9611015A (en) Compound, pharmaceutical composition and process for the treatment of an inflammatory disease susceptible to treatment with a non-toxic non-steroidal anti-inflammatory agent, pharmaceutically acceptable salt, use of a compound
AR022423A1 (en) COMPOUNDS DERIVED FROM ACIDS 2,3,4,5-TETRAHIDRO-1H- [1,4] BENZODIAZEPINA-3-HYDROXAMICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
ES2181803T3 (en) 4-BIARILBUTIRIC OR 5-BIARILPENTANOIC SUBSTITUTED ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALOPROTEASES.
ES2185750T3 (en) USEFUL HYDROXAMIC ACID DERIVATIVES FOR GELATINASA INHIBITION.
BR9509683A (en) Compounds and processes for treating a clinical condition in a mammal for treating a hyperlipidemic condition in a manifer and for preparing a compound
AR007097A1 (en) BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT.
AR010894A1 (en) AROMATIC BICYCLE AMINO ACIDS, A PROCEDURE TO PREPARE THEM, PHARMACEUTICAL PREPARATIONS THAT CONTAIN IT AND THEIR USE OF THEM TO PREPARE A MEDICINAL PRODUCT THAT ACTS AS AN INTEGRIN INHIBITOR.
EA200200520A1 (en) Derivatives of Heterocycloalkylsulfonylpyrazole as an Anti-Inflammatory / Analogical Agents
ES2038172T3 (en) PROCEDURE FOR PREPARING HETERO CYCLIC CARBOXAMIDES.
BG102471A (en) Aromatic ketoacids and their derivatives as inhibitors of matrix metalloproteinases
AR007098A1 (en) MATRIX METALOPROTEASE INHIBITORS, COMPOSITIONS UNDERSTANDING THEM, AND USE OF THEM TO PREPARE PHARMACEUTICAL COMPOSITIONS
MX9307608A (en) CYTOKINE RELEASE INHIBITORS AND IL-1 ANTAGONISTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ES2147629T3 (en) ALKENYL CARBOXYLIC ACID GUANIDINES REPLACED WITH A FLUOROPHENYL GROUP AS NA + / NH + EXCHANGE INHIBITORS, THEIR PREPARATION PROCEDURE AND THEIR USE AS A DIAGNOSTIC MEDICINE OR AGENT AS WELL AS THE CONTAINING MEDICINE.
ES2087623T3 (en) DERIVATIVES OF BENCIMIDAZOLE AS AN ANTIMICROBIAL AGENT AGAINST CAMPYLOBACTER PYLON.
PA8429601A1 (en) INHIBITION OF MATRIX METALOPROTEINASES BY ACIDS 2- (W-AROILALQUIL) -4-BIARIL-4-OXOBUTIRICOS.
AR007100A1 (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED PHENYLALKYL COMPOUNDS AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
AR007096A1 (en) MATRIX METALOPROTEASE INHIBITOR COMPOUND METHOD FOR INHIBITING ITS ACTIVITY, A CONTAINING COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL COMPOSITIONS
ATE40793T1 (en) PHARMACEUTICAL PREPARATION FOR THERAPEUTIC TREATMENT OF RHEUMATIC DISEASES.
MX9206042A (en) NEW DERIVATIVES OF TIADIAZINONES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATION CONTAINING THEM
ECSP972114A (en) BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE
ATE66208T1 (en) DIARYLMETHANE SULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Legal Events

Date Code Title Description
FB Suspension of granting procedure